Your session is about to expire
← Back to Search
Haplo-Cord Transplantation for Blood Cancer
Study Summary
This trial is testing whether it's more important to identify a graft that is at least 5/6 matched and inherited paternal antigen (IPA) targeted or the nucleated cell dose when doing a haplo cord transplant.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have been diagnosed with chronic myelogenous leukemia in a specific phase.I am 18 years old or older.I have been diagnosed with multiple myeloma.I have been diagnosed with myelodysplastic syndrome.I don't have a matching donor available quickly.I have been diagnosed with a blood disorder affecting my hemoglobin.My heart's pumping ability is severely reduced, or my lung tests show poor function.I have a blood disorder requiring a stem cell transplant.My leukemia has returned or didn't respond to treatment.My acute leukemia is in its first remission and is at high risk of coming back.I have been diagnosed with recurrent or refractory lymphoma.I have been diagnosed with a chronic blood disease.I have been diagnosed with aplastic anemia.I have long-term active hepatitis or cirrhosis.I have chronic lymphocytic leukemia that has come back or is hard to treat.My liver and kidney functions are within the required range.I am mostly able to care for myself but may not be able to do active work.My HIV is not under control.
- Group 1: All Patients
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many participants have agreed to join this clinical experiment?
"Affirmative. The clinicaltrials.gov website shows that this medical study is open for enrollment, having first been posted on October 16th 2012 and most recently updated on September 20th 2022. 500 participants will be recruited from two distinct research centers."
What conditions can Total Body Irradiation be utilized to address?
"Total Body Irradiation is regularly used in immunosuppressive treatments. This modality has also been deployed to address dermatitis, atopic conditions, b-cell lymphomas and polyangium."
What is the regulatory status of Total Body Irradiation?
"There is limited clinical evidence for the safety of Total Body Irradiation, thus it has been given an assessment score of 2. Since this is a Phase Two trial, there are no efficacy results available yet."
Has Total Body Irradiation been the subject of additional research efforts?
"The year 1993 marked the initial research into Total Body Irradiation at National Institutes of Health Clinical Center, 9000 Rockville Pike. To date, 1897 clinical trials on this topic have been completed and an additional 945 are currently underway; many of these studies being executed in Chicago, Illinois."
Is there presently an opportunity for participants to join this clinical trial?
"Affirmative. According to information available on clinicaltrials.gov, this medical trial is actively looking for patients with the original listing having been posted on October 16th 2012 and updated recently on September 20th 2022. 500 individuals need to be enrolled from two different locations."
Share this study with friends
Copy Link
Messenger